Sapropterin Dipharma 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued2 / 
affected3  
amended 
on 
T/0009 
Transfer of Marketing Authorisation 
19/12/2022 
30/01/2023 
SmPC, 
Labelling and 
PL 
IB/0008 
C.I.2.a - Change in the SPC, Labelling or PL of a 
13/12/2022 
30/01/2023 
SmPC and PL 
generic/hybrid/biosimilar products following 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0007/G 
This was an application for a group of variations. 
17/11/2022 
30/01/2023 
SmPC 
Product information section 6.3 is updated to reflect the 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
life of the finished product - As packaged for sale 
(supported by real time data) 
shelf-life extension of the finished product Sapropterin 
Dipharma 100 mg soluble tablets (EU/1/21/1620/001-002), 
Sapropterin Dipharma 100 mg powder for oral solution 
(EU/1/21/1620/003) and Sapropterin Dipharma 500 mg 
powder for oral solution (EU/1/21/1620/004) as packaged 
for sale from 24 months to 36 months. 
IA/0006 
B.II.b.4.a - Change in the batch size (including batch 
16/09/2022 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
IB/0005 
B.I.b.2.e - Change in test procedure for AS or 
26/08/2022 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0004/G 
This was an application for a group of variations. 
20/06/2022 
30/01/2023 
Annex II and 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Page 2/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IB/0001 
C.I.6.b - Change(s) to therapeutic indication(s) - 
08/04/2022 
05/05/2022 
SmPC and PL 
Deletion of a therapeutic indication 
IB/0002 
B.II.c.1.b - Change in the specification parameters 
01/04/2022 
n/a 
and/or limits of an excipient - Addition of a new 
specification parameter to the specification with its 
corresponding test method 
IA/0003 
B.II.b.4.b - Change in the batch size (including batch 
14/03/2022 
n/a 
size ranges) of the finished product - Downscaling 
down to 10-fold 
Page 3/3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
